Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | GSK3B | P49841 | 7/20 | 0.35 |
| ▸ | BCHE | P06276 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.32 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1965402 | 0.91 | GSK3B (0.38) | NOS3NOS1NOS2GSK3BGSK3A | |
| SCHEMBL1120024 | 0.90 | GSK3B (0.35) | GSK3BGSK3AKDM4EMAPTTDP1 | |
| SCHEMBL1119959 | 0.89 | GSK3B (0.35) | GSK3BGSK3AKDM4EMAPTTDP1 | |
| SCHEMBL8000687 | 0.89 | GSK3B (0.37) | NOS3NOS1NOS2GSK3BGSK3A | |
| SCHEMBL8003491 | 0.87 | GSK3B (0.32) | GSK3BGSK3A | |
| SCHEMBL1964069 | 0.86 | GSK3B (0.48) | NOS3NOS1NOS2GSK3BGSK3A | |
| SCHEMBL1119969 | 0.85 | GSK3B (0.33) | GSK3BGSK3A | |
| SCHEMBL12680861 | 0.82 | GSK3B (0.36) | NOS3NOS1NOS2GSK3BBCHE | |
| SCHEMBL12680879 | 0.81 | CNR1 (0.35) | GSK3BBCHEACHEGSK3AKDM4E | |
| SCHEMBL12680872 | 0.80 | MAP3K8 (0.35) | GSK3BGSK3AKDM4EMAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-11-07 | — | — | US | disclosed |
| US-8436003-B2 | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-8436003-B2 | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER SCHERING PHARMA AKTIENGESELLESCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | BAYER SCHERING PHARMA AKTIENGESELLESCHAFT (DE) | 2011-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296343-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | NOS3 1999/4885NOS1 3582/4885NOS2 2047/4885 |
| US-20110144131-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES | THPO, IKZF3, TPMT | NOS3 1999/4885NOS1 3582/4885NOS2 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.